Literature DB >> 19442058

Mechanism of drug sensitivity and resistance in melanoma.

Caterina A M La Porta1.   

Abstract

Melanoma is the most aggressive form of skin cancer and advanced stages are inevitably resistant to conventional therapeutic agents. In particular, the inability of undergo apoptosis in response to chemotherapy and other external stimuli poses a selective advantage for tumor progression, metastasis formation as well as resistance to therapy in melanoma. Herein, we will review the molecular mechanisms of sensitivity and/or resistance of the most important drugs used in the treatment of melanoma. Furthermore, the novel strategies to overcome tumor chemoresistance will also be discussed. In particular, we will review the cancer stem cell hypothesis and how the failure of MDR reversal agents might increase the therapeutic index of substrate antineoplastic agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19442058     DOI: 10.2174/156800909788166574

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  28 in total

1.  miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.

Authors:  Shujing Liu; Michael T Tetzlaff; Tao Wang; Ruifeng Yang; Lin Xie; Gao Zhang; Clemens Krepler; Min Xiao; Marilda Beqiri; Wei Xu; Giorgos Karakousis; Lynn Schuchter; Ravi K Amaravadi; Weiting Xu; Zhi Wei; Meenhard Herlyn; Yuan Yao; Litao Zhang; Yingjie Wang; Lin Zhang; Xiaowei Xu
Journal:  Pigment Cell Melanoma Res       Date:  2015-05-16       Impact factor: 4.693

2.  A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis.

Authors:  Guan Jiang; Ai-Jun Jiang; Qian Cheng; Hui Tian; Lian-Tao Li; Jun-Nian Zheng
Journal:  Tumour Biol       Date:  2013-02-21

3.  Revisiting CB1 receptor as drug target in human melanoma.

Authors:  István Kenessey; Balázs Bánki; Agnes Márk; Norbert Varga; József Tóvári; Andrea Ladányi; Erzsébet Rásó; József Tímár
Journal:  Pathol Oncol Res       Date:  2012-03-24       Impact factor: 3.201

4.  Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior.

Authors:  Florence Lefranc; Véronique Mathieu; Robert Kiss
Journal:  World J Biol Chem       Date:  2011-09-26

5.  WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells.

Authors:  Pablo Zapata-Benavides; Edgar Manilla-Muñoz; Diana E Zamora-Avila; Santiago Saavedra-Alonso; Moisés A Franco-Molina; Laura M Trejo-Avila; Guillermo Davalos-Aranda; Cristina Rodríguez-Padilla
Journal:  Oncol Lett       Date:  2012-01-19       Impact factor: 2.967

6.  Interference from LncRNA SPRY4-IT1 restrains the proliferation, migration, and invasion of melanoma cells through inactivating MAPK pathway by up-regulating miR-22-3p.

Authors:  Zhiqing Li; Xuefeng Tang; Song Duan
Journal:  Int J Clin Exp Pathol       Date:  2019-02-01

Review 7.  Stimulation of anti-tumor immunity by photodynamic therapy.

Authors:  Pawel Mroz; Javad T Hashmi; Ying-Ying Huang; Norbert Lange; Michael R Hamblin
Journal:  Expert Rev Clin Immunol       Date:  2011-01       Impact factor: 4.473

8.  miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1.

Authors:  Shujing Liu; Michael T Tetzlaff; Rutao Cui; Xiaowei Xu
Journal:  Am J Pathol       Date:  2012-09-13       Impact factor: 4.307

9.  Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo.

Authors:  Guan Jiang; Chao Sun; Rong-Hua Li; Zhi-Ping Wei; Jun-Nian Zheng; Yan-Qun Liu
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-08       Impact factor: 4.553

10.  Delivery Of Curcumin Nanoliposomes Using Surface Modified With CD133 Aptamers For Prostate Cancer.

Authors:  Qi Ma; Wei Qian; Wei Tao; Yanling Zhou; Boxin Xue
Journal:  Drug Des Devel Ther       Date:  2019-11-28       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.